Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis
研究概览
详细说明
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and limited to the lungs. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis.
The main symptoms of patients with IPF are dyspnea on exertion and a persistent dry cough or mildly productive cough.
In many IPF patients, cough is often the first symptom, preceding dyspnea on exertion sometimes by years. It affects upwards of 70-85% of patients with IPF.
Chronic obstructive pulmonary disease (prevalence rate 4-18%) and asthma (prevalence rate 5.9-9.9%) are the airway disease whose main symptoms are also dyspnea and cough.
To date, the effect of airway disease has not been well studied in patients with idiopathic pulmonary fibrosis, and the prevalence is unknown in Korea.
Unlike idiopathic pulmonary fibrosis, airway disease is a treatable, modifiable disease, so treatment of these diseases may improve QOL in IPF patients.
Therefore, this study's purpose is A. Identify the prevalence of airway disease in IPF patients B. Identify differences in QOL and symptoms according to presence of airway disease C. Identify the symptomatic improvement after active treatment for the airway diseases
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
Seoul、大韩民国
- 招聘中
- Seoul National University Hospital
-
接触：
- Choi Sun Mi
- 电话号码：02-2072-4915
- 邮箱：sunmich81@gmail.com
-
接触：
- PARK HEEMOON
- 邮箱：coramdeo33@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- IPF patients
Exclusion Criteria:
- Patients on systemic steroid
- Patients with acute exacerbation within the last 6 months
- PFT+BDR, MBPT contra-indication
- SpO2 < 90%
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants who have asthma combined with idiopathic pulmonary fibrosis
大体时间：Through study completion, an average of 2 year
|
Confirmation of asthma : pulmonary function test with bronchodilator response or Methacholine provocation test
|
Through study completion, an average of 2 year
|
|
Number of participants who have COPD combined with idiopathic pulmonary fibrosis
大体时间：Through study completion, an average of 2 year
|
Confirmation of COPD : pulmonary function test with bronchodilator response
|
Through study completion, an average of 2 year
|
|
Number of participants who have Eosinophilic bronchitis combined with idiopathic pulmonary fibrosis
大体时间：Through study completion, an average of 2 year
|
Confirmation of Eosinophilic bronchitis : pulmonary function test with bronchodilator response, induced sputum
|
Through study completion, an average of 2 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The difference of CAT scores between patients with airway disease and those without airway disease.
大体时间：baseline and after treating the airway disease for 6~8 weeks
|
Quality of life : COPD assessment test(CAT)
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of SGRQ scores to assess quality of life between patients with airway disease and those without airway disease.
大体时间：baseline and after treating the airway disease for 6~8 weeks
|
Quality of life : St George's Respiratory Questionnaire(SGRQ)
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease.
大体时间：baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : mMRC
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease.
大体时间：baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : 6 minute walking test(6MWT)
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of EQ-5D-VAS scores to assess symptom severity between patients with airway disease and those without airway disease.
大体时间：baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : EQ-5D-VAS
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of CQLQ scores to assess symptom severity between patients with airway disease and those without airway disease.
大体时间：baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ)
|
baseline and after treating the airway disease for 6~8 weeks
|
|
Checking the improvement of CAT score to assess the quality of life between patients with airway disease and those without airway disease
大体时间：After treating the airway disease for 6~8 weeks
|
Quality of life : COPD assessment test(CAT)
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of SGRQ score to assess the quality of life between patients with airway disease and those without airway disease
大体时间：After treating the airway disease for 6~8 weeks
|
Quality of life : St George's Respiratory Questionnaire(SGRQ)
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease
大体时间：After treating the airway disease for 6~8 weeks
|
Symptom severity : mMRC
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease
大体时间：After treating the airway disease for 6~8 weeks
|
Symptom severity : 6 minute walking test(6MWT)
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of EQ-5D-VAS score to assess symptom severity between patients with airway disease and those without airway disease
大体时间：After treating the airway disease for 6~8 weeks
|
Symptom severity : EQ-5D-VAS
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of CQLQ to assess symptom severity between patients with airway disease and those without airway disease
大体时间：After treating the airway disease for 6~8 weeks
|
Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ)
|
After treating the airway disease for 6~8 weeks
|
合作者和调查者
调查人员
- 首席研究员：Choi Sun Mi、Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung institute, Seoul National University College of Medicine, Seoul, Korea
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.